HER2 antibody and oncology surface targets: choose by epitope and application

Choosing for the question

1. Establish which name the target goes by. Several of these targets have two or three names in common use, and catalogues index them differently. Confirm the gene identity before comparing reagents, because apparently different products are frequently the same target.
2. Match the epitope to the application. An extracellular epitope is what a live cell stain or a flow panel needs. An intracellular epitope may be the only one that survives fixation for tissue work. A reagent validated on lysate says nothing about either.
3. Treat scoring as a quantitative assay. If a stain will be used to grade expression, it needs controls spanning the range, a defined scoring rule and evidence that intensity tracks amount. Reagents sold for research are not calibrated for this.
4. Watch for shed and soluble forms. Several surface targets are shed, so a soluble measurement and a cell surface measurement can diverge. State which you measured and do not treat them as the same quantity.
5. Control expression, not just staining. A cell line panel spanning negative, low and high expression is the control that makes a stain interpretable, and it transfers across experiments better than any isotype control.

Presence and amount are different claims

Detecting a target is straightforward with a validated reagent. Grading how much is present requires a calibrated assay, a defined scoring rule and controls across the range, and the difference matters because expression level frequently decides whether a target is actionable.

Where a project will eventually need grading, build the control panel early. Retrofitting quantitation onto a stain designed to show presence is rarely convincing.

Two reagents, one conclusion

For any target whose expression will drive a decision, two independent antibodies against different epitopes agreeing is far stronger evidence than one reagent with a good datasheet. Disagreement is equally useful and better discovered early.

It costs one additional reagent and one experiment, and it is the standard a careful reviewer applies.

A her2 bispecific antibody and the format's purpose

A her2 bispecific antibody binds this page's own target with one arm and something else, usually a T cell receptor chain, with the other, which is what turns a binder into a bridge. The format decides manufacturability and half life more than the binding arms do. For a research reagent the questions are the format, whether it is monovalent for each target, and how it is detected.

A tgf beta antibody and the latent complex

TGF beta is secreted in a latent complex and has to be activated before it binds its receptor, so a tgf beta antibody has to say whether it detects the latent form, the mature growth factor, or both, and a neutralising clone has to be tested against the isoforms. Serum contains it, so the medium is part of the experiment and a serum free control is the honest comparison.

A tgfb antibody, the same factor under the symbol

A tgfb antibody and one listed with the Greek letter spelled out are the same target under two conventions, and the isoform number is the part that matters: the three isoforms have different biology and many clones are isoform specific. The mature dimer runs small and needs a high percentage gel, and heat or acid activation is required before an immunoassay reads total.

A bmp4 antibody and a family with shared processing

BMP4 is made as a precursor, cleaved, and then held by extracellular antagonists, so a bmp4 antibody has to name the form it detects and the family's close relatives are the cross reactivity to rule out. In differentiation work the readout is usually the pathway's phosphorylated effector rather than the ligand, and that pairing is what makes a figure interpretable.

An erk1 antibody and the two bands beside it

ERK1 and ERK2 differ by a few kilodaltons and share most of their sequence, so an erk1 antibody raised on the conserved region reports both and a specific clone should show a single band with a knockdown lane. Activity is read as the doubly phosphorylated activation loop rather than as a level, and the two isoforms are not functionally interchangeable in every tissue.

An e7 antibody and an oncoprotein as a target

An e7 antibody reports a viral oncoprotein rather than a host receptor, and the target is small, nuclear and expressed at low level, which is why most published clones work on a transfected control and few work on tissue. The genotype the immunogen came from decides which infections the clone detects at all.

Common questions

Can a research antibody be used to score expression?

For internal research comparisons with proper controls, yes. For anything informing a clinical decision it cannot, because scoring reagents are validated and labelled for that purpose and research reagents explicitly are not.

Why does a reagent work on a blot and not on tissue?

Different epitope accessibility. Denatured protein on a membrane presents regions that a cross linked tissue section hides, and retrieval has to be optimised per reagent rather than per tissue.

Extracellular or intracellular epitope for a c-Met antibody?

Extracellular for live cells, flow cytometry and anything measuring surface density. Intracellular where fixation has destroyed the surface epitope, accepting that the measurement is then total rather than surface protein.

Browse by service class

• Compare Gene synthesis on advertised prices